Market Overview

ACADIA's Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson's Disease Psychosis Trial

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced successful
top-line results from its pivotal Phase III trial evaluating the
efficacy, tolerability and safety of pimavanserin in patients with
Parkinson's disease psychosis (PDP). Pimavanserin is ACADIA's
proprietary, non-dopaminergic product candidate that selectively blocks
serotonin 5-HT2A receptors. Pimavanserin met the primary
endpoint in the Phase III trial by demonstrating highly significant
antipsychotic efficacy as measured using the 9-item SAPS-PD scale
(p=0.001). Pimavanserin also met the key secondary endpoint for motoric
tolerability as measured using Parts II and III of the Unified
Parkinson's Disease Rating Scale, or UPDRS. These results were further
supported by a highly significant improvement in the secondary efficacy
measure, the Clinical Global Impression Improvement, or CGI-I,

See full press release

Posted-In: News Guidance Contracts Asset Sales Management M&A Global

 

Related Articles (ACAD)

Around the Web, We're Loving...

Get Benzinga's Newsletters